肝包虫病(hydatid disease of liver)是一种人畜共患病,多发生于牧区及养犬人群,内蒙古为疫区之一。近年来,由于对个人卫生的重视,包虫病的患病率随之下降,但随着养犬群体增多,犬是棘球蚴绦虫的携带者和传播者,城市人口的患病率呈上升趋...肝包虫病(hydatid disease of liver)是一种人畜共患病,多发生于牧区及养犬人群,内蒙古为疫区之一。近年来,由于对个人卫生的重视,包虫病的患病率随之下降,但随着养犬群体增多,犬是棘球蚴绦虫的携带者和传播者,城市人口的患病率呈上升趋势,所以,医师对此病应有一定的认识[1]。此病初期进展缓慢,症状轻微,无特异性临床表现,局部压迫或浸润症状只在病灶体积达到一定程度时才可被发现,初期极易发生误诊、漏诊。展开更多
OBJECTIVE: To evaluate the clinical efficacy of a new formulation of albendazole emulsion (AbzE) in cases of liver cystic hydatidosis. METHODS: Two regimens of AbzE (10 mg.kg(-1).d(-1) and 12.5 mg.kg(-1).d(-1)) were g...OBJECTIVE: To evaluate the clinical efficacy of a new formulation of albendazole emulsion (AbzE) in cases of liver cystic hydatidosis. METHODS: Two regimens of AbzE (10 mg.kg(-1).d(-1) and 12.5 mg.kg(-1).d(-1)) were given to 212 patients with liver cystic hydatidosis in courses ranging from 3 months to more than one year. Assessment of drug efficacy was essentially based on imaging signs with ultrasonography as the main tool. Assessments were performed at the end of different courses and in the follow-up study of 1 - 4 years after the cessation of therapy. RESULTS: At the end of therapeutic courses, the overall cure rate of the 212 cases was 74.5%, with a 99.1% effective rate. In the follow-up study, the cure rate was 83.1%, effective rate was 89.3%, ineffective rate was 0.6%, and recurrence rate was 10.2%. The highest cure rate was observed in cases receiving AbzE 12.5 mg.kg(-1).d(-1) for 9 months. Retreatment of recurrent cases with AbzE obtained satisfactory results. CONCLUSIONS: AbzE surpassed other currently used antihydatidosis drugs or formulations with its promising efficacy and mild side effects, and could be recommended as a drug of choice in the treatment of cystic hydatidosis.展开更多
文摘肝包虫病(hydatid disease of liver)是一种人畜共患病,多发生于牧区及养犬人群,内蒙古为疫区之一。近年来,由于对个人卫生的重视,包虫病的患病率随之下降,但随着养犬群体增多,犬是棘球蚴绦虫的携带者和传播者,城市人口的患病率呈上升趋势,所以,医师对此病应有一定的认识[1]。此病初期进展缓慢,症状轻微,无特异性临床表现,局部压迫或浸润症状只在病灶体积达到一定程度时才可被发现,初期极易发生误诊、漏诊。
基金ThisstudywassupportedbytheNinthNationalFive yearPlanKeyResearchProject (No .96 90 6 0 4 0 9)
文摘OBJECTIVE: To evaluate the clinical efficacy of a new formulation of albendazole emulsion (AbzE) in cases of liver cystic hydatidosis. METHODS: Two regimens of AbzE (10 mg.kg(-1).d(-1) and 12.5 mg.kg(-1).d(-1)) were given to 212 patients with liver cystic hydatidosis in courses ranging from 3 months to more than one year. Assessment of drug efficacy was essentially based on imaging signs with ultrasonography as the main tool. Assessments were performed at the end of different courses and in the follow-up study of 1 - 4 years after the cessation of therapy. RESULTS: At the end of therapeutic courses, the overall cure rate of the 212 cases was 74.5%, with a 99.1% effective rate. In the follow-up study, the cure rate was 83.1%, effective rate was 89.3%, ineffective rate was 0.6%, and recurrence rate was 10.2%. The highest cure rate was observed in cases receiving AbzE 12.5 mg.kg(-1).d(-1) for 9 months. Retreatment of recurrent cases with AbzE obtained satisfactory results. CONCLUSIONS: AbzE surpassed other currently used antihydatidosis drugs or formulations with its promising efficacy and mild side effects, and could be recommended as a drug of choice in the treatment of cystic hydatidosis.
